ORPHA:71505
Cancer-associated retinopathy
Also known as: CAR syndrome · Paraneoplastic retinopathy
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
989
89.8th percentile
Trials
0
Interventional, condition-specific
Researchers
1,010
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare paraneoplastic disease of the eye characterized by the presence of extraocular malignancy and circulating autoantibodies against retinal proteins.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019112
- MeSH:D059545
- UMLS:C1321315
Additional Mondo synonyms (1)
paraneoplastic retinopathy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
989 matched papers (471 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
989
989 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
989 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
471 in the last 10 years · high confidence · 89.8th percentile (publications denominator)
Phrase hits: 989 · MeSH hits: 0
Who's working on it?
1,010
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Sobrin L7 papers · 2026
a Department of Ophthalmology , Massachusetts Eye and Ear Infirmary, Harvard Medical School , Boston , Massachusetts , USA .
Papers in Europe PMC - 02Ueno S5 papers · 2021
Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya City, Aichi, 466-8550, Japan, ueno@med.nagoya-u.ac.jp.
Papers in Europe PMC - 03Adamus G3 papers · 2025
Ocular Immunology Laboratory, Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239, USA.
Papers in Europe PMC - 04Dimopoulos MA3 papers · 2024
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
Papers in Europe PMC - 05Hayashi T3 papers · 2021
Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan. taka@jikei.ac.jp.
Papers in Europe PMC - 06Kondo M3 papers · 2021
Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan.
Papers in Europe PMC - 07Liu R3 papers · 2026
Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.
Papers in Europe PMC - 08Terasaki H3 papers · 2019
Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Papers in Europe PMC - 09Andrikopoulou A2 papers · 2023
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
Papers in Europe PMC - 10Androudi S2 papers · 2025
Department of Ophthalmology, University of Thessaly, 41110 Larissa, Greece.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cancer-associated retinopathy" OR "CAR syndrome" OR "Paraneoplastic retinopathy"
MeSH descriptor terms unioned into the query: Paraneoplastic Syndromes, Ocular
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cancer-associated retinopathy" OR "CAR syndrome" OR "Paraneoplastic retinopathy" OR "Paraneoplastic Syndromes, Ocular"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T01:42:00.991Z